Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
暂无分享,去创建一个
Emily M. Thrash | Emma S. Hathaway | Shuqiang Li | K. Livak | S. Gabriel | D. Neuberg | Catherine J. Wu | Helen X. Chen | J. Ritz | F. Hodi | C. Cibulskis | Xiaole Shirley Liu | S. Nikiforow | S. Rodig | P. Armand | M. Davids | R. Soiffer | S. Kim-Schulze | S. Gnjatic | Wandi Zhang | L. Penter | P. Bachireddy | M. Severgnini | C. Cutler | M. Thurin | Haesook T. Kim | J. Antin | V. Ho | N. Cieri | Carrie L. Cibulskis | H. Streicher | Jingxin Fu | J. Koreth | S. Ranasinghe | Aashna Jhaveri | Matthew Nazzaro | Alexandra Savell | Yi Zhang | Teddy Huang | Emma Hathaway | A. Savell | Mariano Severgnini | Livius Penter | Nicoletta Cieri
[1] K. Livak,et al. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy , 2020, Nature Reviews Clinical Oncology.
[2] Emily M. Thrash,et al. High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples , 2020, STAR protocols.
[3] Catherine J. Wu,et al. A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. , 2020, Blood.
[4] Catherine J. Wu,et al. Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. , 2020, The Journal of clinical investigation.
[5] J. Paul Robinson,et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) , 2019, European journal of immunology.
[6] D. Schadendorf,et al. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade , 2019, Cell Research.
[7] Shuqiang Li,et al. RNase H–dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis , 2019, Nature Protocols.
[8] L. Bullinger,et al. Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer , 2019, Oncoimmunology.
[9] A. Goldberg,et al. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets , 2019, Current Oncology Reports.
[10] L. Vago,et al. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. , 2019, Blood.
[11] U. Germing,et al. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment , 2019, International journal of molecular sciences.
[12] R. Nibbs,et al. A guide to chemokines and their receptors , 2018, The FEBS journal.
[13] James Allison,et al. The emerging role of immune checkpoint based approaches in AML and MDS , 2018, Leukemia & lymphoma.
[14] H. Ishwaran,et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.
[15] Catherine J. Wu,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[16] R. Porcher,et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response , 2016, Oncoimmunology.
[17] J. Stenvang,et al. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.
[18] Ryan Emerson,et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.
[19] N. Hacohen,et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. , 2014, Blood.
[20] S. Chasalow,et al. Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.